Immune checkpoint inhibitors (ICIs), such as those targeting the PD-1 (programmed death-1) receptor and its ligand PD-L1, have already demonstrated to provide significant improvements in survival for patients with advanced or metastatic NSCLC [12,23]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.